CTLT Catalent Inc

Price (delayed)

$94.66

Market cap

$15.59B

P/E Ratio

58.07

Dividend/share

N/A

EPS

$1.63

Enterprise value

$17.64B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Catalent, Inc. operates as a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale manufacturing of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing; formulation, development, and manufacturing for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment provides advanced formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Highlights

The net income has soared by 99% YoY and by 37% from the previous quarter
CTLT's equity has soared by 86% year-on-year and by 6% since the previous quarter
Catalent's quick ratio has increased by 28% YoY but it has decreased by 7% from the previous quarter
The stock's price to earnings (P/E) is 19% more than its 5-year quarterly average of 48.8 but 8% less than its last 4 quarters average of 63.3
The debt has grown by 4.3% YoY

Key stats

What are the main financial stats of CTLT
Market
Shares outstanding
164.7M
Market cap
$15.59B
Enterprise value
$17.64B
Valuations
Price to earnings (P/E)
58.07
Price to book (P/B)
5.06
Price to sales (P/S)
4.74
EV/EBIT
39.23
EV/EBITDA
24.78
EV/Sales
5.39
Earnings
Revenue
$3.28B
EBIT
$449.7M
EBITDA
$711.9M
Free cash flow
$22.9M
Per share
EPS
$1.63
Free cash flow per share
$0.14
Book value per share
$18.72
Revenue per share
$19.95
TBVPS
$28.17
Balance sheet
Total assets
$7.98B
Total liabilities
$4.31B
Debt
$3.06B
Equity
$3.07B
Working capital
$1.44B
Liquidity
Debt to equity
1
Current ratio
2.56
Quick ratio
1.86
Net debt/EBITDA
2.88
Margins
EBITDA margin
21.7%
Gross margin
32.2%
Net margin
9.3%
Operating margin
13.5%
Efficiency
Return on assets
3.4%
Return on equity
10.1%
Return on invested capital
8.2%
Return on capital employed
6.4%
Return on sales
13.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTLT stock price

How has the Catalent stock price performed over time
Intraday
-5.15%
1 week
-9.82%
1 month
0.68%
1 year
81.9%
YTD
68.13%
QTD
10.51%

Financial performance

How have Catalent's revenue and profit performed over time
Revenue
$3.28B
Gross profit
$1.05B
Operating income
$441.5M
Net income
$303M
Gross margin
32.2%
Net margin
9.3%
The net income has soared by 99% YoY and by 37% from the previous quarter
The net margin has soared by 60% YoY and by 31% from the previous quarter
Catalent's operating income has surged by 53% YoY and by 12% QoQ
Catalent's gross profit has increased by 26% YoY and by 7% from the previous quarter

Growth

What is Catalent's growth rate over time

Valuation

What is Catalent stock price valuation
P/E
58.07
P/B
5.06
P/S
4.74
EV/EBIT
39.23
EV/EBITDA
24.78
EV/Sales
5.39
The company's EPS has surged by 68% YoY and by 41% QoQ
The stock's price to earnings (P/E) is 19% more than its 5-year quarterly average of 48.8 but 8% less than its last 4 quarters average of 63.3
CTLT's equity has soared by 86% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 20% higher than the last 4 quarters average of 4.2 and 8% higher than the 5-year quarterly average of 4.7
CTLT's price to sales (P/S) is 98% higher than its 5-year quarterly average of 2.4 and 39% higher than its last 4 quarters average of 3.4
The revenue has increased by 24% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Catalent business performance
The company's return on assets rose by 36% QoQ and by 31% YoY
CTLT's return on invested capital is up by 28% year-on-year and by 12% since the previous quarter
The company's return on sales rose by 26% YoY and by 10% QoQ
Catalent's return on equity has increased by 23% QoQ and by 19% YoY

Dividends

What is CTLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTLT.

Financial health

How did Catalent financials performed over time
Catalent's total assets is 85% more than its total liabilities
Catalent's total assets has increased by 30% YoY and by 2.7% from the previous quarter
Catalent's quick ratio has increased by 28% YoY but it has decreased by 7% from the previous quarter
CTLT's equity has soared by 86% year-on-year and by 6% since the previous quarter
The company's debt to equity fell by 44% YoY and by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.